ADCY1 and prostate cancer: High levels of ADCY1 was associated with poor overall survival in patients with metastatic melanoma, glioma, lung and renal tumors (60–63) but was found downregulated in prostate cancer, osteosarcoma, rectal adenocarcinoma metastasis and pancreatic adenocarcinoma (64–67).